Tibet Duo Rui Pharmaceutical Co.Ltd.
Tibet Duo Rui Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical pharmaceutical preparations, intermediates, and raw materials in China. It offers fluid therapy, anesthesiology medication, analgesic medication, and first-aid medication products, as well as sodium acetate ringer's injection; and agent products, such as amoxicillin sodium and clavulan… Read more
Market Cap & Net Worth: Tibet Duo Rui Pharmaceutical Co.Ltd. (301075)
Tibet Duo Rui Pharmaceutical Co.Ltd. (SHE:301075) has a market capitalization of $903.99 Million (CN¥6.63 Billion) as of March 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #12879 globally and #3243 in its home market, demonstrating a -8.41% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tibet Duo Rui Pharmaceutical Co.Ltd.'s stock price CN¥82.91 by its total outstanding shares 80000000 (80.00 Million).
Tibet Duo Rui Pharmaceutical Co.Ltd. Market Cap History: 2021 to 2026
Tibet Duo Rui Pharmaceutical Co.Ltd.'s market capitalization history from 2021 to 2026. Data shows growth from $411.70 Million to $903.99 Million (15.49% CAGR).
Tibet Duo Rui Pharmaceutical Co.Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tibet Duo Rui Pharmaceutical Co.Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.81x
Tibet Duo Rui Pharmaceutical Co.Ltd.'s market cap is 0.81 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $411.70 Million | $529.62 Million | $68.51 Million | 0.78x | 6.01x |
| 2022 | $350.20 Million | $401.05 Million | $20.50 Million | 0.87x | 17.08x |
| 2023 | $288.80 Million | $334.30 Million | $18.85 Million | 0.86x | 15.32x |
| 2024 | $195.93 Million | $240.63 Million | -$62.67 Million | 0.81x | N/A |
Competitor Companies of 301075 by Market Capitalization
Companies near Tibet Duo Rui Pharmaceutical Co.Ltd. in the global market cap rankings as of March 19, 2026.
Key companies related to Tibet Duo Rui Pharmaceutical Co.Ltd. by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Tibet Duo Rui Pharmaceutical Co.Ltd. Historical Marketcap From 2021 to 2026
Between 2021 and today, Tibet Duo Rui Pharmaceutical Co.Ltd.'s market cap moved from $411.70 Million to $ 903.99 Million, with a yearly change of 15.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥903.99 Million | +38.95% |
| 2025 | CN¥650.60 Million | +232.05% |
| 2024 | CN¥195.93 Million | -32.16% |
| 2023 | CN¥288.80 Million | -17.53% |
| 2022 | CN¥350.20 Million | -14.94% |
| 2021 | CN¥411.70 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Tibet Duo Rui Pharmaceutical Co.Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $903.99 Million USD |
| MoneyControl | $903.99 Million USD |
| MarketWatch | $903.99 Million USD |
| marketcap.company | $903.99 Million USD |
| Reuters | $903.99 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.